Verastem reported $-41.48M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Alaunos Therapeutics USD -1.01M 175K Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Curis USD -7.88M 4.63M Dec/2025
Cytokinetics USD -181.23M 2.86M Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
Incyte USD 324.17M 59.7M Mar/2026
Laboratory Of America USD 410.1M 28.1M Mar/2026
Novartis USD 4.24B 171M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
TG Therapeutics USD 34.8M 15.7M Mar/2026
Verastem USD -41.48M 23.2M Dec/2025